
PCSA — Processa Pharmaceuticals Inc
NASDAQ · Healthcare · Biotechnology
$2.05
+$0.00 (+0.00%)
Processa Pharmaceuticals Inc (PCSA) is a biotechnology company listed on NASDAQ. It is led by George K. Ng Esq., J.D., based in 601 21st Street, Vero Beach, FL, United States, 32960, with about 12 employees. Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells. Its oncology pipeline includes NGC-Cap (PCS6422), a combination of PCS6422 and capecitabine, which is in a Phase 2 clinical trial to treat metastatic breast, colorectal, hepatocellular, pancreatic, gastric, and other solid tumors; and NGC-Iri (PCS11T), an analog of an active metabolite of irinotecan, which is in preclinical trials to treat lung, pancreatic, ovarian, colorectal, gastric, cervical, and other cancers. The company also develops non-oncology drugs consisting of PCS499, an oral tablet of the deuterated analog of pentoxifylline that has completed a Phase 2b clinical trial for the treatment of primary glomerular diseases, including focal segmental glomerulosclerosis (FSGS), IgA, and membranous nephropathy, as well as ulcerative necrobiosis lipoidica; and PCS12852, a highly specific and potent 5HT4 agonist that has completed a Phase 2 clinical trial for the treatment of gastroparesis and constipation disorders. It has license agreements with Elion Oncology, Inc., Aposense, Ltd., Yuhan Corporation, and Sun Pharmaceuticals Industries Limited. Processa Pharmaceuticals, Inc. was founded in 2015 and is based in Vero Beach, Florida.
Net income was -$3.4M. PCSA currently screens at market cap $5.9M.
Use this PCSA page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the PCSA quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the PCSA SEC filings page. Lician reads the product cache first so this HTML stays unique to Processa Pharmaceuticals Inc even when a live quote feed is slow.
About Processa Pharmaceuticals Inc
Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells. Its oncology pipeline includes NGC-Cap (PCS6422), a combination of PCS6422 and capecitabine, which is in a Phase 2 clinical trial to treat metastatic breast, colorectal, hepatocellular, pancreatic, gastric, and other solid tumors; and NGC-Iri (PCS11T), an analog of an active metabolite of irinotecan, which is in preclinical trials to treat lung, pancreatic, ovarian, colorectal, gastric, cervical, and other cancers. The company also develops non-oncology drugs consisting of PCS499, an oral tablet of the deuterated analog of pentoxifylline that has completed a Phase 2b clinical trial for the treatment of primary glomerular diseases, including focal segmental glomerulosclerosis (FSGS), IgA, and membranous nephropathy, as well as ulcerative necrobiosis lipoidica; and PCS12852, a highly specific and potent 5HT4 agonist that has completed a Phase 2 clinical trial for the treatment of gastroparesis and constipation disorders. It has license agreements with Elion Oncology, Inc., Aposense, Ltd., Yuhan Corporation, and Sun Pharmaceuticals Industries Limited. Processa Pharmaceuticals, Inc. was founded in 2015 and is based in Vero Beach, Florida.
PCSA Key Statistics
Market Cap
$5.91M
Volume
42,522
Previous Close
$2.17
Day Range
$2.15 – $2.28
P/B Ratio
2.27
EPS
-$3.87
Revenue
$0.00
Net Income
-$11.85M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
12
PCSA Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$11.85M | -$11.12M | -$27.42M | -$11.43M |
| EPS (Diluted) | -$3.87 | -$8.48 | -$34.05 | $0.00 |
Total Assets
$3.23M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$1.19M
Operating Cash Flow
-$11.25M
Free Cash Flow
$0.00
Processa Pharmaceuticals Inc Company Information
- CEO & Director
- George K. Ng Esq., J.D.
- Headquarters
- 601 21st Street, Vero Beach, FL, United States, 32960
- Phone
- 772 453 2899
- IPO / Founded
- 2017-10-10
- Sector
- Healthcare
- Industry
- Biotechnology